Evidence map›Paper›PMID 30852397›Full record

ArticleNeuroImage. Clinical2019

A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms.

Leah M Fleming, Daniel C Javitt, Cameron S Carter, Joshua T Kantrowitz, Ragy R Girgis, Lawrence S Kegeles, John D Ragland, Richard J Maddock, Tyler A Lesh, Costin Tanase and 9 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in NeuroImage. Clinical, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Neuroimaging Biomarkers in Schizophrenia.The American journal of psychiatry · 2021
    Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Leah M FlemingDepartment of Psychiatry, Yale University, New Haven, CT, United States of America; Interdepartmental Neuroscience Program, Yale University, New Haven, CT, United States of America.
Daniel C JavittDepartment of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States of America; Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, NY, United States of America.
Cameron S CarterDepartment of Psychiatry, University of California, Davis, United States of America.
Joshua T KantrowitzDepartment of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States of America; Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, NY, United States of America.
Ragy R GirgisDepartment of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States of America.
Lawrence S KegelesDepartment of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States of America.
John D RaglandDepartment of Psychiatry, University of California, Davis, United States of America.
Richard J MaddockDepartment of Psychiatry, University of California, Davis, United States of America.
Tyler A LeshDepartment of Psychiatry, University of California, Davis, United States of America.
Costin TanaseDepartment of Psychiatry, University of California, Davis, United States of America.
James RobinsonNathan Kline Institute for Psychiatric Research, Orangeburg, New York, NY, United States of America.
William Z PotterNational Institute of Mental Health, Rockville, MD, United States of America.
Marlene CarlsonDepartment of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States of America.
Melanie M WallDepartment of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States of America; National Institute of Mental Health, Rockville, MD, United States of America.
Tse-Hwei ChooDepartment of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States of America.
Jack GrinbandDepartment of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States of America.
Jeffrey LiebermanDepartment of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, United States of America.
John H KrystalDepartment of Psychiatry, Yale University, New Haven, CT, United States of America.
Philip R CorlettDepartment of Psychiatry, Yale University, New Haven, CT, United States of America. Electronic address: philip.corlett@yale.edu.
Columbia University Irving Medical Center · USUniversity of California, Davis · USNathan Kline Institute for Psychiatric Research · USYale University · USNational Institute of Mental Health · US

Funding

Interdepartmental Neuroscience Program (INP)T32NS041228 · NINDS · YALE UNIVERSITY · PI Charles A Greer, Marina R Picciotto · 2001 to 2026
$12.0M
NIDA NIH HHS HHSN271201200007CNINDS NIH HHS T32 NS041228
6 · The paper itself

Abstract

Ketamine is an uncompetitive N-methyl-d-aspartate (NMDA) glutamate receptor antagonist. It induces effects in healthy individuals that mimic symptoms associated with schizophrenia. We sought to root these experiences in altered brain function, specifically aberrant resting state functional connectivity (rsfMRI). In the present study, we acquired rsfMRI data under ketamine and placebo in a between-subjects design and analyzed seed-based measures of rsfMRI using large-scale networks, dorsolateral prefrontal cortex (DLPFC) and sub-nuclei of the thalamus. We found ketamine-induced alterations in rsfMRI connectivity similar to those seen in patients with schizophrenia, some changes that may be more comparable to early stages of schizophrenia, and other connectivity signatures seen in patients that ketamine did not recreate. We do not find any circuits from our regions of interest that correlates with positive symptoms of schizophrenia in our sample, although we find that DLPFC connectivity with ACC does correlate with a mood measure. These results provide support for ketamine's use as a model of certain biomarkers of schizophrenia, particularly for early or at-risk patients.

Indexed as

AdolescentAdultBrainExcitatory Amino Acid AntagonistsFemaleHumansKetamineMagnetic Resonance ImagingMaleMiddle AgedNerve NetSchizophreniaYoung AdultExcitatory Amino Acid AntagonistsKetamineFunctional connectivityKetaminePsychosisResting state

Identifiers

PMID30852397
PMCPMC6411494
OpenAlexW2920514419

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.